OverviewSuggest Edit
23andMe is a consumer genetics and research company. It helps individuals to understand their own genetic information through DNA analysis technologies and web-based interactive tools. The сompany enables people to gain insights into their ancestry and genetic makeup.
| Type | Private | |
| Founded | 2006 | |
| HQ | Sunnyvale, CA, US | Map |
| Website | 23andme.com | |
| Employee Ratings | More | |
| Overall Culture | A+ | More |
Recent NewsAll News
- Stocks making the biggest moves midday: Home Depot, 23andMe, Tencent Music and more
- Stocks making the biggest moves premarket: Disney, Airbnb, 23andMe, DoorDash and others
- Consumer genetics company 23andMe loss widens in first earnings report since going public
- 23andMe Reports FY2022 First Quarter Financial Results
Key People/Management at 23andMe
Anne Wojcicki
CEO and Co-Founder
Bill Richards
Vice President, Target and Drug Discovery
Astrid Ruefli-Brasse
Vice President and Head of Discovery and Translational Research, Director
Kimberly Noel
Medical Director
Joyce Tung
Vice President, Research
Jeffrey Pollard
Director of Medical Affairs
23andMe Office Locations
23andMe has an office in Sunnyvale
Sunnyvale, CA, US (HQ)
223 N Mathilda Ave
23andMe Financials and Metrics
Summary Metrics
Founding Date | 2006 |
23andMe total Funding | $912.5 m |
23andMe latest funding size | $82.5 m |
Time since last funding | 9 months ago |
23andMe investors | Sequoia Capital, New Enterprise Associates, Google, DST Global, Google Ventures, Fidelity Investments, Mohr Davidow Ventures, Altimeter Capital, Xfund, Genentech, Johnson & Johnson Development Corporation, MPM Capital, National Institutes of Health, Illumina, Casdin Capital, Stephens Investment Management, GV, Anne Wojcicki, Euclidean Capital, Fidelity Management, Sergey Brin, GlaxoSmithKline, Wallenberg Foundations, NewView Capital, Raj Luhar, WuXi Venture Fund |
23andMe's latest funding round in December 2020 was reported to be $82.5 m. In total, 23andMe has raised $912.5 m. 23andMe's latest valuation is reported to be $2.5 b.
23andMe Revenue
23andMe's revenue was reported to be $475 m in Y, 2018
| USD | |
|---|---|
Revenue (Y, 2018) | 475.0m |
Market valuation | 2.5b |
- Source: Sharespost
| USD | Y, 2018 |
|---|---|
Revenue/Employee | 833.9k |
23andMe Acquisitions / Subsidiaries
| Company Name | Date | Deal Size |
|---|---|---|
| CureTogether | July 10, 2012 |
23andMe Cybersecurity Score
23andMe Online and Social Media Presence
93.7k Twitter followers
23andMe has 93.7k Twitter Followers. The number of followers has increased 0.1% month over month and increased 0.7% quarter over quarter
23andMe's Trends
Twitter Engagement Stats for @23andMe
18k
Tweets
7k
Following
93.7k
Followers
14
Tweets last 30 days
14.5
Avg. likes per Tweet
100%
Tweets with engagement
23andMe Company Culture
Overall Culture
A+
82/100
CEO Rating
A+
92/100
Compensation
A
83/100
Diversity
A-
83/100
23andMe News and Updates
August 17, 2021
Stocks making the biggest moves midday: Home Depot, 23andMe, Tencent Music and more
Names on the move ahead of the open.
August 13, 2021
Stocks making the biggest moves premarket: Disney, Airbnb, 23andMe, DoorDash and others
Names on the move ahead of the open.
August 13, 2021
Consumer genetics company 23andMe loss widens in first earnings report since going public
Consumer genetics company 23andMe posted its first quarterly earnings as a public company on Friday, after it merged with Richard Branson's pecial-purpose acquisition corporation, or SPAC, VG Acquisition Corp. in June. The company said it had a net loss of $42 million in its fiscal first quarter t…
August 13, 2021
23andMe Reports FY2022 First Quarter Financial Results
First quarter revenue up 23% over prior yearStrong cash balance of $770 millionContinuing to advance therapeutics portfolio to drive future revenue growth
July 29, 2021
23andMe to Report FY2022 First Quarter Financial Results
SUNNYVALE, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 first quarter before the market opens on Friday, August 13, 2021. The …
June 21, 2021
Industry Leaders Join 23andMe Board of Directors
Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe’s Board as the Company Sets to Accelerate Personalized Healthcare Based on Human Genetics Dr. Valerie Montgomery Rice and Peter Taylor Join 23andMe’s Board as the Company Sets to Accelerate Personalized Healthcare Based on Human Genetics
23andMe Blogs
September 21, 2021
Helping to Drive Discovery in 23andMe’s Therapeutics Division
Xin Fang’s interest in science started at the dinner table, listening to her parents talking about what they did each day. Both her mom and dad are plant scientists. Her mom...
The post Helping to Drive Discovery in 23andMe’s Therapeutics Division appeared first on 23andMe Blog.
September 17, 2021
23andMe Offers Revelations for Adoptee Searching for His Siblings
Adoptee and filmmaker Aaron Harris used 23andMe to help him learn more about himself, and his connections to his birth family.
The post 23andMe Offers Revelations for Adoptee Searching for His Siblings appeared first on 23andMe Blog.
September 15, 2021
Taking Control for a Healthier Pregnancy
23andMe released a new 23andMe+ report on gestational diabetes report, which affects an estimated 6 to 9 percent of those expecting. The report looks at a person's ethnicity and more than 6,000 genetic variants associated with developing gestational diabetes mellitus, commonly known as gestational …
September 14, 2021
Talking About Rare Disease with Senior Scientist Suyash Shringarpure
23andMe senior scientist in statistical genetics, Suyash Shringarpure, Ph.D. talks about 23andMe's research model and how it offers a surprising opportunity in the study of rare diseases.
The post Talking About Rare Disease with Senior Scientist Suyash Shringarpure appeared first on 23andMe Blog.
September 08, 2021
Raising Awareness About Fatty Liver Disease
Wayne Eskridge CEO of the Fatty Liver Foundation wants to raise awareness about fatty liver disease, and help people make changes toward better health.
The post Raising Awareness About Fatty Liver Disease appeared first on 23andMe Blog.
September 01, 2021
Making 23andMe More Inclusive for All Genders
We’ve made some important updates to give customers greater control over tailoring their product experience so it more accurately reflects their gender. 23andMe now allows customers to distinguish between their...
The post Making 23andMe More Inclusive for All Genders appeared first on 23andMe Blog…
23andMe Frequently Asked Questions
When was 23andMe founded?
23andMe was founded in 2006.
Who are 23andMe key executives?
23andMe's key executives are Anne Wojcicki, Bill Richards and Astrid Ruefli-Brasse.
How many employees does 23andMe have?
23andMe has 717 employees.
What is 23andMe revenue?
Latest 23andMe annual revenue is $475 m.
What is 23andMe revenue per employee?
Latest 23andMe revenue per employee is $662.5 k.
Who are 23andMe competitors?
Competitors of 23andMe include Antylia Scientific, Gene By Gene and FamilyTreeDNA.
Where is 23andMe headquarters?
23andMe headquarters is located at 223 N Mathilda Ave, Sunnyvale.
Where are 23andMe offices?
23andMe has an office in Sunnyvale.
How many offices does 23andMe have?
23andMe has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies